** Shares of Imugene IMU.AX rise as much as 14.1% to A$0.105, their biggest intraday pct gain since May 26

** Cell therapy co says U.S. Food and Drug Administration grants Fast Track Designation to azer-cel (azercabtagene zapreleucel)

** Fast Track Designation for two indications: relapsed or refractory Chronic Lymphocytic Leukaemia/ Small Lymphocytic Lymphoma (CLL/SLL) and relapsed or refractory Marginal Zone Lymphoma (MZL)

** Azer-cel an off-the-shelf, CD19-directed CAR T-cell therapy engineered to overcome logistical constraints of autologous CAR T therapies, co says

** YTD, IMU shares down 74.3%